We are testing a new drug called AMG 509 for men with metastatic castration-resistant prostate cancer. The study aims to evaluate its safety and how it may help manage this advanced stage of cancer.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a form of prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body, leading to more aggressive symptoms.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
